Expanded treatment choices and strategies for improved management of CHB


Hadziyannis SJ, Costamena A, Laras A, Hadziyannis E. Predictors/determinants of sustained virological response (SVR) and of HBsAg loss following long term adeovir dipivoxil (ADV) therapy in HBeAg-negative chronic hepatitis (CHB). Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 874.

Han SB, Chang T, Chao Y, et al. Five years of continuous entecavir for nucleoside-naive HBeAg(+) chronic hepatitis B: results from study ETV-901. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 893.

Heathcote E, Gane EJ, deMan RA, et al. Two-year tenofovir disoproxil fumarate (TDF) treatment and adeovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31—November 4, 2008; San Francisco, California. Abstract 158.


Lau GK, Leung N, Hui CK, et al. Clevudine was superior to lamivudine in the patients with HBeAg (+) chronic hepatitis B. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 911.


Marcellin P, Brunetto M, Bonino F, et al. In patients with HBeAg-negative chronic hepatitis B HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance 4 years post-treatment. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 919.


Schollmeyer J, Lutgehetmann M, Volz T, et al. Combination of entecavir and tenofovir as a rescue therapy is safe and highly efficient in cirrhotic HBV mono-infected patients with the history of multiple previous treatment failures. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 985.


REVEAL data support link between HBV and HCC


Office of Minority Health releases strategies to address HBV in AA/NIHOPI communities


Selected Readings (continued)

CDC issues new guidelines for HBV screening


NIH Consensus Development Conference ignites controversy on the management of HBV


2008 Update on resistance to HBV therapies


Fung SK, Mazzulli T, El-Kashab M, et al. Lamivudine-resistant mutation among treatment-naive hepatitis B patients is common and may be associated with treatment failure. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 888.


Snow-Lampart A, Chappell BJ, Curtis M, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg QD. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, California. Abstract 977.
Selected Readings (continued)


Benefits and risks of combination therapy for HBV (SIDEBAR)


Terrault NA. Benefits and risks of combination therapy for hepatitis B. Program and abstracts of the NIH Consensus Development Conference: Management of Hepatitis B. October 20–22, Bethesda, Maryland.


Distribution of chronic HBV infection worldwide, 2006 (SIDEBAR)

